Dicerna Pharmaceuticals Inc (DRNA) was Reiterated by Stifel to “Buy” while Lowering the Price Target of the company shares to $ 13 from a previous price target of $16 . Stifel advised their investors in a research report released on Jun 30, 2016.
Many Wall Street Analysts have commented on Dicerna Pharmaceuticals Inc. Shares were Reiterated by Stifel on May 10, 2016 to “Buy” and Lowered the Price Target to $ 16 from a previous price target of $20 .Chardan Capital Markets Initiated Dicerna Pharmaceuticals Inc on Apr 5, 2016 to “Neutral”, Price Target of the shares are set at $5.
Dicerna Pharmaceuticals Inc closed down -0.14 points or -4.43% at $3.02 with 7,57,756 shares getting traded on Wednesday. Post opening the session at $3.23, the shares hit an intraday low of $2.88 and an intraday high of $3.38 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
Dicerna Pharmaceuticals Inc. (Dicerna) is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company uses its RNA interference (RNAi) technology platform to build a pipeline in these therapeutic areas. The Company is in collaboration with two companies for oncology development programs with the global pharmaceutical company Kyowa Hakko Kirin Co. Ltd. (KHK). Its current development programs include Dacryocystorhinostomy (DCR)-PH1 for Primary Hyperoxaluria Type 1 (PH1) Additional Liver Targets DCR-MYC for MYC-related cancers and KRAS Program. Dicerna’s discovery approach is based on double-stranded RNA molecules called Dicer Substrate siRNA (DsiRNA).